Intestinal barrier function and serum concentrations of rifampin, isoniazid and pyrazinamide in patients with pulmonary tuberculosis

Brazilian Journal of Infectious Diseases

Volumn 13, Issue 3, 2009, Pages 210-217

  Façanha, Mônica C ^a   Gondim, Argina M B ^b   Pinheiro, Valéria G F ^a   Barroso, Elizabeth C ^a   Peloquin, Charles A ^c   Guerrant, Richard L ^a,d   Lima, Aldo A M ^a,d  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^b Health Center Carlos Ribeiro   (Brazil)

^c NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Bioavailability of antimycobacterial drugs; Intestinal barrier function; Isoniazid; Pyrazinamide; Rifampin; Tuberculosis

Indexed keywords

ISONIAZID; LACTULOSE; MANNITOL; PYRAZINAMIDE; RIFAMPICIN;

ADULT; ARTICLE; BODY MASS; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; FEMALE; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTESTINE; INTESTINE ABSORPTION; INTESTINE MUCOSA PERMEABILITY; LUNG TUBERCULOSIS; MALE;

ADULT; ANTITUBERCULAR AGENTS; CASE-CONTROL STUDIES; FEMALE; HUMANS; INTESTINAL ABSORPTION; ISONIAZID; MALE; PYRAZINAMIDE; RIFAMPIN; TIME FACTORS; TUBERCULOSIS, PULMONARY;

EID: 77749295027     PISSN: 14138670     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1413-86702009000300011     Document Type: Article

References (34)

1. World Health Organization (WHO) (2006) Global tuberculosis control: surveillance, planning, financing. Geneva, 2006.
2. Brasil. Ministério da Saúde. Vigilância em saúde: dados e indicadores selecionados. Brasília, DF; 2005.
3. Fortaleza. Secretaria Municipal de Saúde. Tuberculose. Boletim de Saúde de Fortaleza 1995;9(1).
4. Perri G.D., Bonora S. Which agents should we use for treatment of multidrug-resistant Mycobacterium tuberculosis? J Antimicrob Chemother 2004;54:593-602.
5. Faustini A., Hall A.J., Perucci C.A. Risk factors for multidrugresistant tuberculosis in Europe: a systematic review. Thorax 2006; 61:158-63.
6. Raviglione M.C., Smith I.M. XDR tuberculosis - Implications for global public health. N England J Med 2006;356:656-9.
7. Barroso E.C., Rodrigues J.L.N., Pinheiro V.G.F., Campelo C.L. Prevalência da tuberculose multirresistente no Estado do Ceará, 1990-1999. J Pneumol 2001;27:310-14.
8. Mehta J.B., Shantaveerapa H., Byrd J.R.P. et al. Utility of rifampin blood leveis in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to -f respond to routine directly observed therapy. Chest 2001;120:1520-4.
9. Peloquin C.A., Macphee A.A., Berning S.E. Malabsorption of antimicrobial medications. N Engl J Med 2001;329:1122-3.
10. Pinheiro V.G.F., Ramos L.M.A., Monteiro H.S. et al. Intestinal permeability and malabsorption of rifampin and isoniazida in active pulmonary tuberculosis. Braz J Infect Dis 2006;10:374-9.
11. Tappero J.W., Bradford W.Z., Agertonn T.B. et al. Serum concentrations of antimycobacterial drugs in patients with tuberculosis in Botswana. Clin Infect Dis 2005;41:461-9.
12. Berning S.E., Huitt G.A., Iseman M.D., Peloquin C.A. Malabsorption of antituberculosis medications by a patient with AIDS. New Engl J Med 1992;327:1817-8.
13. Gurumurthy P., Ramachandra G., Kumar A.K.H. et al. Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis. Clin Infect Dis 2004;38:280-3.
14. Gurumurthy P., Ramachandran G., Kumar A.K.H. et al. Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency. Antimicrobial Agents Chemother 2004;48:4473-5.
15. Peloquin C.A., Nitta A.T., Buran W.J. et al. Low antituberculosis drug concentrations in patients with AIDS. Ann Pharmacother 1996;30:919-23.
16. Sahai J., Gallicano K., Swick L. et al. Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. Ann Intern Med 1997;127:289-93.
17. Choudhri S.A., Hawken M., Gathua S. et al. Pharmacokinetics of antmycobacterial drugs in patients with tuberculosis, AIDS, and diarrhea. Clin Infect Dis 1997;25:104-11.
18. Kimerling M.E., Phillips P., Patterson P. et al. Low Serum Antimycobacterial Drug Levels in Non-HIV-Infected Tuberculosis Patients. Chest 1998;113:1178-83.
19. McIlleron H., Wash P., Burger A. et al. Determinants of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol Pharmacokinetics in a Cohort of Tuberculosis Patients. Antimicrobial Agents Chemother 2006; 50(4):1170-7.
20. Um S.W., Lee S.W., Kwon S.Y. et al. Low serum concentrations of anti-tuberculosis drugs and determinants of their serum levels.Int J Tuberc Lung Dis 2007;11(9):972-8.
21. Broutet S., Queiroz Sousa A., Basílio F.P. et al. Prevalence of HIV-1, HIV-2 and HTLV antibody, in Fortaleza, Ceara, Brazil, 1993-1994. Int J STD AIDS 1996;7:365-9.
22. Aertgeerts B., Buntinx F., Ansoms S., Fevery J. Screening properties of questionnaires and laboratory tests for the detection of alcohol abuse or dependence in a general practice population. Br J General Practice 2001;51:206-17.
23. Vinson D.C., Galliher J.M., Reidinger C., Kappus J.A. Comfortably Engaging: Which Approach to Alcohol Screening Should We Use? Ann Fam Med 2004;2:398-404.
24. World Health Organization (WHO). Physical status: the use and interpretation of anthropometry. Geneva, Report of a WHO Expert Committee. Série de Informes Técnicos 1995;854:462.
25. Barboza Jr., M.S., Silva T.M., Guerrant R.L., Lima A.A.M. Measurement of intestinal permeability using manitol and lactulose in children with diarrheal diseases. Braz J Med Biol Res 1999;32:1499-1504.
26. Peloquin C.A., Bulpitt A.E., Jaresko G.S. et al. Pharmacokinetics of pyrazinamide under fasting conditions, with food, and with antacids. Pharmacotherapy 1998;18:1205-11.
27. Peloquin C.A., Bulpitt A.E., Jaresko G.S. et al. Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids. Antimicrob Agents Chemother 1999;43:568-72.
28. Peloquin C.A., Namdar R., Dodge A.A., Nix D.E. Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids. Int J Tuberc Lung Dis 1999;3:703-10.
29. Peloquin C.A. Using therapeutic drug monitoring to dose the antimycobacterial drug. Clin Chest Med 1997;18:79-87.
30. th Ed. The McGraw-Hill Co., New York, NY, 2007.
31. Caws M., Drobniewski F.A. Molecular techniques in the diagnosis of Mycobacterium tuberculosis and the detection of drug resistance. Ann NY Acad Sci 2001;953:138-45.
32. Ducati R.G., Ruffino-Netto A., Basso L.A., Santos D.S. The resumption of consumption. A review on tuberculosis. Mem Inst Oswaldo Cruz 2006;101:697-714.
33. Keshavarzian A., Fields J.Z., Vaeth J., Holmes E.W. The differing effects of acute and chronic alcohol on gastric and intestinal permeability. Am J Gastrenterol 1994;89:2205-12.
34. Marcial M.A., Carlson S.L., Madara J.L. Partitioning of paracellular conductances along the ileal crypt-villus axis: a hypothesis based structural analysis with detailed consideration to tight-junction structure-function relationships. J Memb Biol 1984;80:59-70.